Nanobiotix S.A. ADR (NBTX)

$NBTX $SPWH $GSRT

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Nanobiotix. Is that bullish or bearish? $NBTX #Nanobiotix #RsiOverbought #NASDAQ

$NBTX Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

$NBTX (+7.2% pre) Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer https://ooc.bz/l/63465

Guggenheim updates rating for Nanobiotix ( $NBTX ) to Buy, target set at 12 → 8.

$NBTX AGMH very good price to jump in at 0.042 has to get to a dollar soon if I post again mybad ..,..

WATCHLIST MAR 21 2025 $ALNY Alnylam Secures FDA Approval Of sNDA For Its RNAi Therapeutic, AMVUTTRA, For Treatment Of ATTR-CM In Adults To Reduce Cardiovascular Mortality, Cardiovascular Hospitalizations And Urgent Heart Failure Visits $ARBB ARB IOT shares are trading higher after the company announced an order to deploy its Smart IOT Farming System for a palm oil plantation that spreads 2K acres. The company stated it expects to generate $13 million in annual recurring revenue from the deal. $NBTX NANOBIOTIX Presents Data From Two Phase 1 Studies Evaluating JNJ-1900 At European Lung Cancer Conference $ALOT AstroNova Executes Waiver And Amendment Of Its Revolving Credit Facility And Term Loans With Bank Of America $MFH Mercurity Fintech Holding Announced Its Wholly Owned Subsidiary, Chaince Securities, Has Successfully Received Approval For Its Continuing Membership Application From The Financial Industry Regulatory Authority

$NBTX looking interesting

Gapping up: $RGC +63.3% $HROW +18.8% $FINV +11.8% $NBTX +9.6% $KODK +6.8%

$NBTX $JNJ Nanobiotix amends global licensing agreement with Janssen Pharmaceutica Nanobiotix (NBTX) announced the execution of another step in its financial strategy through the amendment of the company's global licensing agreement with Janssen Pharmaceutica, a Johnson & Johnson (JNJ) company. The amendment removes Nanobiotix's funding obligation for NANORAY-312 and releases Johnson & Johnson from select future potential milestone payments, while safeguarding potential milestone payments. Johnson & Johnson will assume nearly all remaining costs for the ongoing pivotal Phase 3 trial through completion, less a small portion of costs that will remain covered by Nanobiotix. Revisions to potential future milestone payments in the amendment total $105M while maintaining first significant milestones and hundreds of millions in potential milestone payments related to the clinical programs for cisplatin-ineligible head and neck cancer and stage 3 unresectable non-small cell lung cancer expected by Nanobiotix in the coming years. The global licensing agreement, now valued up to approximately $2.6B, includes Nanobiotix eligibility for potential success-based payments that include: $1.77B, in the aggregate, in potential development, regulatory, and sales milestones related to the first programs including cisplatin-ineligible head and neck cancer and unresectable stage 3 non-small cell lung cancer; $650M, in the aggregate, in potential additional development, regulatory, and sales milestones related to five new indications that may be developed by Johnson & Johnson at its sole discretion; $165M, in the aggregate, in potential development, regulatory, and sales milestones for China, South Korea, Singapore, and Thailand. In addition to the approximately $2.6B in potential milestones outlined above, Nanobiotix remains eligible for $220M in potential development and regulatory milestones per new indication that may be developed by Nanobiotix, in alignment with Johnson & Johnson. Tiered double-digit potential royalties in the low 10s to low 20s remain unchanged. The amended agreement has enabled Nanobiotix to extend cash visibility to mid-2026, while continuing to explore additional financing options-preferably non-dilutive-to further extend runway into 2027. Nanobiotix also expects a meaningful reduction of operational cash burn going forward, as the ongoing Phase 3 study previously represented a significant portion of the company's operating costs.